

Supplementary Table 3. Total adverse events in ATG and placebo subjects from month 12 to month 24

	<u>ATG</u> <u>Participants</u> (n=38)	<u>Events</u>	<u>Placebo</u> <u>Participants</u> (n=20)	<u>Events</u>	<u>Total</u> <u>Participants</u> (n=58)	<u>Events</u>
Adverse Events	35 (92%)	387	17 (85%)	164	52 (90%)	551
Metabolism and nutrition disorders	30 (79%)	263	12 (60%)	123	42 (72%)	386
Hypoglycaemia	30 (79%)	260	10 (50%)	120	40 (69% 0)	380
Hyperglycaemia	1 (3%)	1	1 (5%)	2	2 (3%)	3
Diabetes mellitus inadequate control	1 (3%)	1	0	0	1 (2%)	1
Diabetic ketoacidosis	0	0	1 (5%)	1	1 (2%)	1
Ketosis	1 (3%)	1	0	0	1 (2%)	1
Infections and infestations	22 (58%)	34	6 (30%)	9	28 (48%)	43
Upper respiratory tract infection	9 (24%)	12	4 (20%)	6	13 (22%)	18
Sinusitis	4 (11%)	5	0	0	4 (7%)	5
Bronchitis	3 (8%)	4	0	0	3 (5%)	4
Viral infection	3 (8%)	4	0	0	3 (5%)	4
Acrodermatitis	1 (3%)	1	0	0	1 (2%)	1
Adenoiditis	1 (3%)	1	0	0	1 (2%)	1
Ear infection	1 (3%)	1	0	0	1 (2%)	1
Gingival infection	0	0	1 (5%)	1	1 (2%)	1
Herpes virus infection	1 (3%)	1	0	0	1 (2%)	1
Influenza	1 (3%)	1	0	0	1 (2%)	1
Nasopharyngitis	1 (3%)	1	0	0	1 (2%)	1
Pharyngitis	0	0	1 (5%)	1	1 (2%)	1
Pharyngitis streptococcal	0	0	1 (5%)	1	1 (2%)	1
Salmonellosis	1 (3%)	1	0	0	1 (2%)	1
Tonsillitis	1 (3%)	1	0	0	1 (2%)	1
Tooth infection	1 (3%)	1	0	0	1 (2%)	1
Respiratory, thoracic and mediastinal disorders	11 (29%)	11	4 (20%)	5	15 (26%)	16
Cough	3 (8%)	3	1 (5%)	1	4 (7%)	4
Oropharyngeal pain	2 (5%)	2	2 (10%)	2	4 (7%)	4
Sinus congestion	2 (5%)	2	1 (5%)	1	3 (5%)	3
Bronchospasm	0	0	1 (5%)	1	1 (2%)	1
Dyspnoea	1 (3%)	1	0	0	1 (2%)	1
Epistaxis	1 (3%)	1	0	0	1 (2%)	1
Nasal congestion	1 (3%)	1	0	0	1 (2%)	1
Rhinitis allergic	1 (3%)	1	0	0	1 (2%)	1
Gastrointestinal disorders	10 (26%)	14	2 (10%)	4	12 (20%)	18
Abdominal pain upper	1 (3%)	1	1 (5%)	1	2 (3%)	2
Diarrhoea	1 (3%)	1	1 (5%)	1	2 (3%)	2
Nausea	2 (5%)	2	0	0	2 (3%)	2
Oral disorder	1 (3%)	3	0	0	1 (2%)	3
Abdominal pain	0	0	1 (5%)	1	1 (2%)	1
Constipation	1 (3%)	1	0	0	1 (2%)	1
Dyspepsia	0	0	1 (5%)	1	1 (2%)	1
Food poisoning	1 (3%)	1	0	0	1 (2%)	1
Gastric ulcer	1 (3%)	1	0	0	1 (2%)	1
Gastritis	1 (3%)	1	0	0	1 (2%)	1
Gastrointestinal pain	1 (3%)	1	0	0	1 (2%)	1

	<u>ATG</u> <u>Participants</u> (n=38)	<u>Events</u>	<u>Placebo</u> <u>Participants</u> (n=20)	<u>Events</u>	<u>Total</u> <u>Participants</u> (n=58)	<u>Events</u>
Gastroesophageal reflux disease	1 (3%)	1	0	0	1 (2%)	1
Irritable bowel syndrome	1 (3%)	1	0	0	1 (2%)	1
Skin and subcutaneous tissue disorders	7 (18%)	9	5 (25%)	8	12 (20%)	17
Lipohypertrophy	0	0	2 (10%)	4	2 (3%)	4
Acne	1 (3%)	1	1 (5%)	1	2 (3%)	2
Rash	1 (3%)	2	0	0	1 (2%)	2
Skin lesion	1 (3%)	2	0	0	1 (2%)	2
Dermatitis contact	0	0	1 (5%)	1	1 (2%)	1
Eczema	0	0	1 (5%)	1	1 (2%)	1
Erythema	1 (3%)	1	0	0	1 (2%)	1
Hyperkeratosis	1 (3%)	1	0	0	1 (2%)	1
Ingrowing nail	1 (3%)	1	0	0	1 (2%)	1
Lipoatrophy	0	0	1 (5%)	1	1 (2%)	1
Urticaria	1 (3%)	1	0	0	1 (2%)	1
Injury, poisoning and procedural complications	11 (29%)	15	1 (5%)	1	12 (20%)	16
Excoriation	2 (5%)	3	0	0	2 (3%)	3
Foot fracture	2 (5%)	2	0	0	2 (3%)	2
Joint sprain	2 (5%)	2	0	0	2 (3%)	2
Concussion	1 (3%)	2	0	0	1 (2%)	2
Skin laceration	1 (3%)	2	0	0	1 (2%)	2
Ankle fracture	1 (3%)	1	0	0	1 (2%)	1
Back injury	1 (3%)	1	0	0	1 (2%)	1
Contusion	1 (3%)	1	0	0	1 (2%)	1
Fibula fracture	1 (3%)	1	0	0	1 (2%)	1
Sunburn	0	0	1 (5%)	1	1 (2%)	1
Musculoskeletal and connective tissue disorders	5 (13%)	9	3 (15%)	3	8 (14%)	12
Back pain	2 (5%)	2	3 (15%)	3	5 (9%)	5
Arthralgia	2 (5%)	2	0	0	2 (3%)	2
Patellofemoral pain syndrome	1 (3%)	2	0	0	1 (2%)	2
Muscle spasms	1 (3%)	1	0	0	1 (2%)	1
Myalgia	1 (3%)	1	0	0	1 (2%)	1
Scoliosis	1 (3%)	1	0	0	1 (2%)	1
General disorders and administration site conditions	4 (11%)	4	2 (10%)	4	6 (10%)	8
Influenza like illness	1 (3%)	1	2 (10%)	2	3 (5%)	3
Fatigue	1 (3%)	1	1 (5%)	1	2 (3%)	2
Chest pain	1 (3%)	1	0	0	1 (2%)	1
Malaise	1 (3%)	1	0	0	1 (2%)	1
Pyrexia	0	0	1 (5%)	1	1 (2%)	1
Blood and lymphatic system disorders	3 (8%)	5	2 (10%)	2	5 (9%)	7
Neutropenia	2 (5%)	2	1 (5%)	1	3 (5%)	3
Leukopenia	2 (5%)	2	0	0	2 (3%)	2
Lymphadenopathy	0	0	1 (5%)	1	1 (2%)	1
Lymphopenia	1 (3%)	1	0	0	1 (2%)	1
Psychiatric disorders	2 (5%)	3	2 (10%)	3	4 (7%)	6
Depression	2 (5%)	3	2 (10%)	2	4 (7%)	5
Suicidal ideation	0	0	1 (5%)	1	1 (2%)	1
Immune system disorders	4 (11%)	5	0	0	4 (7%)	5

	<u>ATG</u> <u>Participants</u> (n=38)	<u>Events</u>	<u>Placebo</u> <u>Participants</u> (n=20)	<u>Events</u>	<u>Total</u> <u>Participants</u> (n=58)	<u>Events</u>
Seasonal allergy	4 (11%)	5	0	0	4 (7%)	5
Nervous system disorders	3 (8%)	3	1 (5%)	1	4 (7%)	4
Headache	2 (5%)	2	1 (5%)	1	3 (5%)	3
Presyncope	1 (3%)	1	0	0	1 (2%)	1
Investigations	2 (5%)	2	1 (5%)	1	3 (5%)	3
Blood immunoglobulin A decreased	1 (3%)	1	0	0	1 (2%)	1
Glycosylated haemoglobin increased	0	0	1 (5%)	1	1 (2%)	1
Urine albumin/creatinine ratio increased	1 (3%)	1	0	0	1 (2%)	1
Eye disorders	2 (5%)	2	0	0	2 (3%)	2
Dry eye	1 (3%)	1	0	0	1 (2%)	1
Lacrimation increased	1 (3%)	1	0	0	1 (2%)	1
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	2 (5%)	2	0	0	2 (3%)	2
Acrochordon	1 (3%)	1	0	0	1 (2%)	1
Melanocytic naevus	1 (3%)	1	0	0	1 (2%)	1
Reproductive system and breast disorders	2 (5%)	2	0	0	2 (3%)	2
Amenorrhoea	1 (3%)	1	0	0	1 (2%)	1
Ovarian cyst	1 (3%)	1	0	0	1 (2%)	1
Cardiac disorders	1 (3%)	1	0	0	1 (2%)	1
Aortic valve incompetence	1 (3%)	1	0	0	1 (2%)	1
Endocrine disorders	1 (3%)	1	0	0	1 (2%)	1
Thyroid mass	1 (3%)	1	0	0	1 (2%)	1
Pregnancy, puerperium and perinatal conditions	1 (3%)	1	0	0	1 (2%)	1
Pregnancy	1 (3%)	1	0	0	1 (2%)	1
Renal and urinary disorders	1 (3%)	1	0	0	1 (2%)	1
Nephrolithiasis	1 (3%)	1	0	0	1 (2%)	1